BACKGROUNDThe WHO recommends shorter TB preventive treatment (TPT) regimens and decentralised delivery models to improve effectiveness.
BACKGROUND: There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially with more recently available drugs and regimens.
BACKGROUND: For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis.
INTRODUCTION: Understanding sex and gender differences during outbreaks is critical to delivering an effective response.
BACKGROUND: In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability.
BACKGROUND: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent.
We investigated people living with HIV (PLWH)'s exposure to COVID-19 pandemic stressors and their association with distress, psychological growth, and substance use.
BACKGROUND: Malaria infections in pregnancy are a major cause of maternal morbidity and neonatal mortality in sub-Saharan Africa.
BACKGROUND: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive.
BACKGROUND: The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen and six months or longer for Bdq and delamanid (Dlm) in t
